Ayan Maity

Main Group Lewis Acid-Mediated Transformations of Transition-Metal Hydride Complexes

This Review highlights stoichiometric reactions and elementary steps of catalytic reactions involving cooperative participation of transition-metal hydrides and main group Lewis acids. Included are reactions where the transition-metal hydride acts as a reactant as well as transformations that form the metal hydride as a product. This Review is divided by reaction type, illustrating the diverse roles that Lewis acids can play in mediating transformations involving transition-metal hydrides as either reactants or products. We begin with a discussion of reactions where metal hydrides form direct adducts with Lewis acids, elaborating the structure and dynamics of the products of these reactions. The bulk of this Review focuses on reactions where the transition metal and Lewis acid act in cooperation, and includes sections on carbonyl reduction, H2 activation, and hydride elimination reactions, all of which can be promoted by Lewis acids. Also included is a section on Lewis acid-base secondary coordination sphere interactions, which can influence the reactivity of hydrides. Work from the past 50 years is included, but the majority of this Review focuses on research from the past decade, with the intent of showcasing the rapid emergence of this field and the potential for further development into the future.

Room-temperature synthesis of cyclometalated iridium(III) complexes: kinetic isomers and reactive functionalities

Cyclometalated iridium(III) complexes have been prepared in high yields from base-assisted transmetalation reactions of cis-bis(aquo)iridium(III) complexes with boronated aromatic proligands. Reactions proceed at room temperature. Potassium hydroxide and potassium phosphate are effective supporting bases. Kinetic, meridional isomers are isolated because of the mildness of the new technique. Syntheses are faster with KOH, but the gentler base K3PO4 broadens the reactions scope. Complexes of chelated ketone, aldehyde, and alcohol complexes are reported that bind iridium through formally neutral oxygen and formally anionic carbon. The new complexes luminesce with microsecond-scale lifetimes at 77 K and nanosecond-scale lifetimes at room temperature; emission quenches in air. Two complexes, an aldehyde and its reduced (alcohol) derivative, are crystallographically characterized. Their bonding is examined with density-functional theory calculations. Time-dependent computations suggest that the Franck–Condon triplet states of these complexes have mixed orbital parentage, arising from one-particle transitions that mingle through configuration interaction.

Steric and Electronic Influence of Aryl Isocyanides on the Properties of Iridium(III) Cyclometalates.

Cyclometalated iridium complexes with efficient phosphorescence and good electrochemical stability are important candidates for optoelectronic devices. Isocyanide ligands are strong-field ligands: when attached to transition metals, they impart larger HOMO-LUMO energy gaps, engender higher oxidative stability at the metal center, and support rugged organometallic complexes. Aryl isocyanides offer more versatile steric and electronic control by selective substitution at the aryl ring periphery. Despite a few reports of alkyl isocyanide of cyclometalated iridium(III), detailed studies on analogous aryl isocyanide complexes are scant. We report the synthesis, photophysical properties, and electrochemical properties of 11 new luminescent cationic biscyclometalated bis(aryl isocyanide)iridium(III) complexes. Three different aryl isocyanides--2,6-dimethylphenyl isocyanide (CNAr(dmp)), 2,6-diisopropylphenyl isocyanide (CNAr(dipp)), and 2-naphthyl isocyanide (CNAr(nap))--were combined with four cyclometalating ligands with differential π-π* energies--2-phenylpyridine (ppy), 2,4-difluorophenylpyridine (F2ppy), 2-benzothienylpyridine (btp), and 2-phenylbenzothiazole (bt). Five of them were crystallographically characterized. All new complexes show wide redox windows, with reduction potentials falling in a narrow range of -2.02 to -2.37 V and oxidation potentials spanning a wider range of 0.97-1.48 V. Efficient structured emission spans from the blue region for [(F2ppy)2Ir(CNAr)2]PF6 to the orange region for [(btp)2Ir(CNAr)2]PF6, demonstrating that isocyanide ligands can support redox-stable luminescent complexes with a range of emission colors. Emission quantum yields were generally high, reaching a maximum of 0.37 for two complexes, whereas btp-ligated complexes had quantum yields below 1%. The structure of the CNAr ligand has a minimal effect on the photophysical properties, which are shown to arise from ligand-centered excited states with very little contribution from metal-to-ligand charge transfer in most cases.

A Metal-containing Nucleoside That Possesses Both Therapeutic and Diagnostic Activity against Cancer

Background: Nucleoside transport is an important therapeutic target against cancer. Results: Cell-based studies show that a metal-containing nucleoside displays anti-cancer effects and diagnostic properties against adherent cancers. Conclusion: A metal-containing nucleoside functions as a biophotonic substrate for a nucleoside transporter. Significance: A novel nucleoside with combined therapeutic and diagnostic activities provides a tool to treat cancer. Nucleoside transport is an essential process that helps maintain the hyperproliferative state of most cancer cells. As such, it represents an important target for developing diagnostic and therapeutic agents that can effectively detect and treat cancer, respectively. This report describes the development of a metal-containing nucleoside designated Ir(III)-PPY nucleoside that displays both therapeutic and diagnostic properties against the human epidermal carcinoma cell line KB3-1. The cytotoxic effects of Ir(III)-PPY nucleoside are both time- and dose-dependent. Flow cytometry analyses validate that the nucleoside analog causes apoptosis by blocking cell cycle progression at G2/M. Fluorescent microscopy studies show rapid accumulation in the cytoplasm within 4 h. However, more significant accumulation is observed in the nucleus and mitochondria after 24 h. This localization is consistent with the ability of the metal-containing nucleoside to influence cell cycle progression at G2/M. Mitochondrial depletion is also observed after longer incubations (Δt ∼48 h), and this effect may produce additional cytotoxic effects. siRNA knockdown experiments demonstrate that the nucleoside transporter, hENT1, plays a key role in the cellular entry of Ir(III)-PPY nucleoside. Collectively, these data provide evidence for the development of a metal-containing nucleoside that functions as a combined therapeutic and diagnostic agent against cancer.